These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28216404)

  • 21. Discovery of dual orexin receptor antagonists with rat sleep efficacy enabled by expansion of the acetonitrile-assisted/diphosgene-mediated 2,4-dichloropyrimidine synthesis.
    Roecker AJ; Mercer SP; Harrell CM; Garson SL; Fox SV; Gotter AL; Prueksaritanont T; Cabalu TD; Cui D; Lemaire W; Winrow CJ; Renger JJ; Coleman PJ
    Bioorg Med Chem Lett; 2014 May; 24(9):2079-85. PubMed ID: 24704030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of 1H-pyrazolo[3,4-b]pyridines as potent dual orexin receptor antagonists (DORAs).
    Behnke D; Cotesta S; Hintermann S; Fendt M; Gee CE; Jacobson LH; Laue G; Meyer A; Wagner T; Badiger S; Chaudhari V; Chebrolu M; Pandit C; Hoyer D; Betschart C
    Bioorg Med Chem Lett; 2015 Dec; 25(23):5555-60. PubMed ID: 26522950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia.
    Betschart C; Hintermann S; Behnke D; Cotesta S; Fendt M; Gee CE; Jacobson LH; Laue G; Ofner S; Chaudhari V; Badiger S; Pandit C; Wagner J; Hoyer D
    J Med Chem; 2013 Oct; 56(19):7590-607. PubMed ID: 23964859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics.
    Janto K; Prichard JR; Pusalavidyasagar S
    J Clin Sleep Med; 2018 Aug; 14(8):1399-1408. PubMed ID: 30092886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia.
    Futamura A; Suzuki R; Tamura Y; Kawamoto H; Ohmichi M; Hino N; Tokumaru Y; Kirinuki S; Hiyoshi T; Aoki T; Kambe D; Nozawa D
    Bioorg Med Chem; 2020 Jul; 28(13):115489. PubMed ID: 32482533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lemborexant (Dayvigo) for insomnia.
    Med Lett Drugs Ther; 2020 Jun; 62(1601):97-100. PubMed ID: 32724021
    [No Abstract]   [Full Text] [Related]  

  • 27. Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs.
    Kumar A; Chanana P; Choudhary S
    Pharmacol Rep; 2016 Apr; 68(2):231-42. PubMed ID: 26922522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDM-878.
    Maehara S; Yuge N; Higashi C; Ota T; Furukawa J; Takeuchi T
    Neuropsychopharmacol Rep; 2020 Jun; 40(2):182-189. PubMed ID: 32337858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suvorexant as an orexin antagonist may regulate serum glucose levels in psychiatric patients with insomnia.
    Nakamura M; Nagamine T
    Psychiatry Clin Neurosci; 2017 Dec; 71(12):844. PubMed ID: 28945327
    [No Abstract]   [Full Text] [Related]  

  • 30. Mechanism of action of suvorexant.
    Stahl SM
    CNS Spectr; 2016 Jun; 21(3):215-8. PubMed ID: 27322687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lemborexant: First Approval.
    Scott LJ
    Drugs; 2020 Mar; 80(4):425-432. PubMed ID: 32096020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders.
    Muehlan C; Vaillant C; Zenklusen I; Kraehenbuehl S; Dingemanse J
    Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1063-1078. PubMed ID: 32901578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.
    De Boer P; Drevets WC; Rofael H; van der Ark P; Kent JM; Kezic I; Parapatics S; Dorffner G; van Gerven J; Beneš H; Keicher C; Jahn H; Seiden DJ; Luthringer R
    J Psychopharmacol; 2018 Jun; 32(6):668-677. PubMed ID: 29848147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual orexin receptor antagonists for insomnia in youth with neurodevelopmental disorders: a case series and review.
    Besterman AD; Jeste SS
    Eur Child Adolesc Psychiatry; 2023 Mar; 32(3):527-531. PubMed ID: 34611728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suvorexant (Belsomra) for insomnia.
    Med Lett Drugs Ther; 2015 Mar; 57(1463):29-31. PubMed ID: 25719996
    [No Abstract]   [Full Text] [Related]  

  • 37. A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia.
    Ziemichód W; Grabowska K; Kurowska A; Biała G
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suvorexant for the Treatment of Insomnia in Adolescents.
    Kawabe K; Horiuchi F; Ochi M; Nishimoto K; Ueno SI; Oka Y
    J Child Adolesc Psychopharmacol; 2017 Nov; 27(9):792-795. PubMed ID: 28520464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suvorexant: scientifically interesting, utility uncertain.
    Keks NA; Hope J; Keogh S
    Australas Psychiatry; 2017 Dec; 25(6):622-624. PubMed ID: 28994603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant.
    Born S; Gauvin DV; Mukherjee S; Briscoe R
    Regul Toxicol Pharmacol; 2017 Jun; 86():181-192. PubMed ID: 28279667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.